Impact on quality of life and factors associated with relapse in Dermatophytoses
DOI:
https://doi.org/10.66344/jpad.v32i2.1902Abstract
Background Dermatophytosis have a significant impairment in quality of life of the patients. The aim of this study was to evaluate quality of life in patients with dermatophytosis using Dermatology life quality index (DLQI), correlate DLQI with disease characteristics and assess the risk factors for relapse.
Methods This was a cross-sectional observational study based in a tertiary care hospital in central Nepal carried out from September 2020 to February 2021. A detailed clinical profile of each patient was recorded and a Nepali dermatology life quality index (DLQI) questionnaire was used to evaluate quality of life in these patients and was correlated with disease characteristics. A logistic regression analysis was done to assess the predictors of relapse.
Results A total of 128 patients were included in the study. The median age of study population was 26 years. Mean DLQI score was 12.39(±0.55) with no difference in male and female. Most of the patients (45.3%) had very large effect (score 11-20) on the quality of life. The quality of life had positive correlation with the increasing body surface area (p=.007) and itch scale (p=<0.001) and negative correlation with the duration of the disease (p=.015). Males were 3.9 times more likely to relapse. There was no statistical association between recurrence and use of steroids, sharing towel, age of patient and duration of disease.
Conclusion Dermatophytosis causes large impact on the quality of life of the patient. Larger body surface area involvement and large itch scale (measured in last 2 days) are associated with higher impairment in quality of life. Males are more likely to have higher rates of relapse.
References
1. Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51(4):2-15.
2. Walker SL, Shah M, Hubbard VG, et al. Skin disease is common in rural Nepal : results of a point prevalence study. Br J Dermatol. 2008;158(2):334-8.
3. Shrestha D, Gurung D, Rosdahl I. Prevalence of skin diseases and impact on quality of life in hilly region of Nepal. Journal of Institute of Medicine Nepal. 2013;34(3):44-9.
4. Poudyal Y, Rajbhandari S. Pattern of Skin Diseases in Patients Visiting Universal College of Medical Sciences-Teaching Hospital (UCMS-TH) from the Three Districts of Terai Region in Nepal. J Univers Coll Med Sci. 2014;2(3):3-8.
5. Shrestha P, Mikrani JA. Pattern of Dermatological Disease and its Relation to Gender in Lumbini Medical College Teaching Hospital. J Lumbini Med Coll. 2015;3(1):16-8.
6. Naglot A, Shrimali DD, Nath BK, et al. Original Research Article Recent Trends of Dermatophytosis in Northeast India (Assam) and Interpretation with Published Studies. Int J Curr Microbiol App Sci. 2015;4(11):111-20.
7. Dogra S, Uprety S. The menace of chronic and recurrent dermatophytosis in India: Is the problem deeper than we perceive? Indian Dermatol Online J. 2016;7(2):73-6.
8. 8Rajagopalan M, Inamadar A, Mittal A, et al. Expert Consensus on The Management of Dermatophytosis in India (ECTODERM India). BMC Dermatol. 2018;18(1):6.
9. Mushtaq S, Faizi N, Amin SS, et al. Impact on quality of life in patients with dermatophytosis. Australas J Dermatol. 2020;61(2):e184-8.
10. Rajashekar TS, Nandigonnanavar S, Kuppuswamy SK, et al. Dermatology life quality index in patients with persisting and recurrent dermatophytoses. Int J Res Dermatol. 2019;5(1):139-43.
11. Narang T, Bhattacharjee R, Singh S, et al. Quality of life and psychological morbidity in patients with superficial cutaneous dermatophytosis. Mycoses. 2019;62(8):680-5.
12. Patro N, Panda M, Jena A. The menace of superficial dermatophytosis on the quality of life of patients attending referral hospital in Eastern India: A cross-sectional observational study. Indian Dermatol Online J. 2019;10(3):262-6.
13. Phan NQ, Blome C, Fritz F, et al. Assessment of Pruritus Intensity : Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic Pruritus. Acta Derm Venereol. 2012;92:502-7.
14. Jenkins LHH, Spencer LED, Weissgerber LAJ, et al. Correlating an 11-Point Verbal Numeric Rating Scale to a 4-Point Verbal Rating Scale in the Measurement of Pruritis. J Perianesth Nurs. 2009;24(3):152-5.
15. Finlay A, Khan G. Dermatology Life Quality Index (DLQI)- a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-6.
16. Basra MKA, Fenech R, Gatt RM, et al. The Dermatology Life Quality Index 1994-2007: A comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159:997-1035.
17. Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659-64.
18. Khadka DK, Agrawal S, Dhali TK. Methotrexate Versus Methotrexate Plus Folic Acid in the Treatment of Moderate to Severe Plaque Psoriasis: A Randomized Clinical-Trial. Nepal J Dermatol Venereol Leprol. 2016;14(1):29-36.
19. Agrawal S, Rijal A, Bhattarai S. Impact of patch testing on quality of life in patients with hand eczema: A follow-up study. Kathmandu Univ Med J. 2013;11(43):216-20.
20. Poudyal Y, Parajuli N, Dahal SC, et al. The Study of Quality of Life in Patient with Vitiligo. Birat J Health Sci. 2020;5(3):1206-9.
21. Jin-Gang A, Sheng-Xiang X, Sheng-Bin X, et al. Quality of life of patients with scabies. J Eur Acad Dermatology Venereol. 2010;24(10):1187-91.
22. Das DN, Das DS. A study to assess the quality of life (QOL) of patients suffering from tinea corporis attending dermatology OPD of a tertiary care centre of Eastern India. Int J Med Res Rev. 2019;7(6):490-5.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Sushil Paudel, Sudip Parajuli, Upama Paudel
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
